Jump to content

TRIDENT-1 is enrolling participants in a Phase 2 multi-center study evaluating an investigational drug repotrectinib for the treatment of individuals with ROS1+


LUNGevityHunter

Recommended Posts

TRIDENT-1 is enrolling participants in a Phase 2 multi-center study evaluating an investigational drug repotrectinib for the treatment of individuals with ROS1+ advanced non-small cell lung cancer (NSCLC) as well as individuals with NTRK+ advanced solid tumors.

 

Patient Website link: http://trident1study.com

Patient eBrochure link: https://online.flippingbook.com/view/462279568/

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...